Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
SODIUM CLODRONATE
Beacon Pharmaceuticals Ltd
800 Milligram
Film Coated Tablet
2011-11-11
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Clasteon 800mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 1000mg of disodium clodronate tetrahydrate, equivalent to 800mg of anhydrous sodium clodronate. Each tablet contains 128.24 mg sodium. For a full list of excipients, see 6.1. 3 PHARMACEUTICAL FORM Film coated tablets. White, oval, convex tablet with breakline. The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Sodium clodronate is indicated for the management of osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in patients with carcinoma of the breast or multiple myeloma. Sodium clodronate tablets are also indicated for the maintenance of clinically acceptable serum calcium levels in patients with hypercalcaemia of malignancy initially treated with an intravenous bisphosphonate. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adequate fluid intake should be maintained during treatment. A Clasteon 800mg tablet may be divided into two to ease swallowing, but the halves have to be taken at the same time of administration. Clasteon tablets should not be crushed or dissolved before intake. _Adults_: The recommended daily dose is 2 tablets (1600mg sodium clodronate) taken as a single dose. If clinically necessary, the dose may be increased, but is not recommended to exceed 3200 mg daily. Intravenous clodronate is recommended for the treatment of hypercalcaemia due to malignancy. However, if oral therapy is used, a high starting dose of 2400 or 3200 mg daily should be used and, depending on the individual response, this can be reduced gradually to 1600 mg daily in order to maintain nor Read the complete document